Application of monoterpene indole alkaloid in preparation of antifungal drugs
Monoterpene indole alkaloids are repurposed for antifungal drugs, showing potent inhibitory effects on fungi like Aspergillus niger and Fusarium oxysporum, expanding their application beyond antibacterial uses and utilizing natural extraction for safety.
Patent Information
- Application Number
- CN202411303937.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-19
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-09-19
AI Technical Summary
Current research on monoterpene indole alkaloids primarily focuses on their antibacterial activity against Mycobacterium smegmatis and Mycobacterium tuberculosis, with limited application in antifungal treatments for fungal infections.
The use of monoterpene indole alkaloids, specifically rhazinilam and rhazinal, in the formulation of antifungal drugs, targeting fungi such as Aspergillus niger, Sclerotinia sclerotiorum, and Fusarium oxysporum, with formulations including pharmaceutically acceptable carriers and excipients, and concentrations ranging from 5-100 μg/mL.
Monoterpene indole alkaloids demonstrate significant antifungal activity against various fungal species, providing a new approach for antifungal drug development and leveraging their natural extraction from plants for safety advantages.
Smart Images

Figure CN119055638A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of antifungal treatment, and in particular to the application of monoterpene indole alkaloids in the preparation of antifungal drugs. Background Art
[0002] Monoterpene indole alkaloids have a wide range of biological activities and can be used to treat a variety of diseases. On the other hand, due to their complex structure, although they are difficult to mass produce through chemical synthesis, they can be directly extracted from plants in nature. This feature gives monoterpene indole alkaloids the advantage of being natural medicines.
[0003] There have been many cases of monoterpene indole alkaloids being used in the pharmaceutical field that have been publicly reported. For example, patent publication number CN113480538A discloses the use of a monoterpene indole alkaloid derivative in the preparation of a drug for preventing or treating cerebral ischemia-reperfusion injury. For another example, patent publication number CN115433185A discloses a monoterpene indole alkaloid and its preparation method and application, and the application fields include anti-Mycobacterium smegmatis, anti-Mycobacterium tuberculosis and treatment of pulmonary tuberculosis.
[0004] However, current research on monoterpene indole alkaloids mostly applies them to the treatment of bacterial pathogens such as Mycobacterium smegmatis and Mycobacterium tuberculosis. There are no reports on monoterpene indole alkaloids having antifungal activity for the prevention and treatment of fungal infections. This limitation restricts the application of monoterpene indole alkaloids in a wider range of fields. Summary of the invention
[0005] In order to overcome the above-mentioned shortcomings of the prior art, the object of the present invention is to provide the use of monoterpene indole alkaloids in the preparation of antifungal drugs.
[0006] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions: The use of monoterpene indole alkaloids in the preparation of antifungal drugs, wherein the structural formula of the monoterpene indole alkaloids is shown in formula (A) or formula (B): (A) (B).
[0007] Preferably, the antifungal drug includes one or more of a drug for inhibiting fungal growth, a drug for killing fungi, and a drug for treating diseases caused by fungal infection.
[0008] Preferably, the fungi include one or more of the phylum Ascomycota, Basidiomycota, Deuteromycota, and Zygomycota.
[0009] Preferably, the fungus comprises one or more of Aspergillus niger, Sclerotinia sclerotiorum, and Fusarium oxysporum.
[0010] Preferably, the antifungal drug comprises monoterpene indole alkaloids and pharmaceutically acceptable salts thereof.
[0011] Preferably, the antifungal drug comprises monoterpene indole alkaloids and a pharmaceutically acceptable carrier or excipient.
[0012] Preferably, the pharmaceutically acceptable carrier or excipient includes one or more of a diluent, a binder, a lubricant, a solvent, a stabilizer, and a filler.
[0013] Preferably, the solvent includes one or more of dimethyl sulfoxide, N,N-dimethylformamide, ethanol, propylene glycol, acetone, and ethyl acetate.
[0014] Preferably, the concentration of the monoterpene indole alkaloids in the antifungal drug is 5-100 μg / mL.
[0015] The beneficial effects of the present invention are: Since fungi are eukaryotic organisms, they have significant differences in biology and pharmacology from bacterial pathogens in the fields where monoterpene indole alkaloids are commonly used. The inventors unexpectedly discovered through research that the monoterpene indole alkaloids provided by the present invention have significant antifungal activity and show inhibitory effects on a variety of fungi, which can provide new ideas for the preparation of antifungal drugs. In addition, monoterpene indole alkaloids can be extracted from natural plants and have the safety advantage of natural drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 It is a schematic diagram of the comparison of the inhibition zones of Preparation Example 1, Preparation Example 2 and ketoconazole after culturing on PDA agar at 28° C. for 3 days, wherein Figure A is a schematic diagram of the inhibition zone of Preparation Example 1, Figure B is a schematic diagram of the inhibition zone of Preparation Example 2, and Figure C is a schematic diagram of the inhibition zone of ketoconazole; Figure 2 Schematic diagram of the mycelial growth of Aspergillus niger cultured on PDA agar at 28° C. in Preparation Example 1, Preparation Example 2 and ketoconazole at different concentrations; Figure 3 Schematic diagram of the mycelial growth of Sclerotinia sclerotiorum cultured on PDA agar at 28° C. in Preparation Example 1, Preparation Example 2 and ketoconazole at different concentrations; Figure 4 Schematic diagram of the mycelial growth of Fusarium oxysporum cultured on PDA agar at 28° C. in Preparation Example 1, Preparation Example 2 and ketoconazole at different concentrations. DETAILED DESCRIPTION
[0017] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments of the specification. Those of ordinary skill in the art will be able to implement the present invention based on these descriptions. In addition, the embodiments of the present invention involved in the following description are generally only embodiments of a part of the present invention, rather than all embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work should fall within the scope of protection of the present invention.
[0018] Preparation Example 1 10 kg of Bousigonia angustifolia, a plant of the genus Bousigonia in the Apocynaceae family, was used as raw material and extracted with methanol at room temperature for 3 times, 20 L each time. The methanol extracts were combined and the methanol was recovered under reduced pressure and low temperature (40°C) to obtain the extract. The extract was dissolved in an appropriate amount of 0.5% hydrochloric acid aqueous solution and extracted three times with an equal volume of ethyl acetate. The remaining acid aqueous solution was adjusted to pH 7-8 with 10% ammonia water, and extracted again with an equal volume of ethyl acetate three times. The ethyl acetate extracts were combined and the ethyl acetate was recovered under reduced pressure and low temperature (40°C) to obtain 90 g of the extract. The extract was first separated on a silica gel column and eluted with a gradient of dichloromethane-methanol (1:0-0:1) to obtain 10 elution sites (Fr1-Fr10). Elution site 1 (Fr1) 8.4 g was separated by reverse phase C18 medium pressure column chromatography and eluted with a gradient of methanol-water (10:90-100:0) to obtain 18 elution sites (Sub1-Sub18). Sub12 was purified by reverse phase C18 preparative liquid phase, and gradient eluted with acetonitrile-water (30:70-45:55, v / v) to obtain the compound rhazinilam (21 mg). The structural formula of rhazinilam is shown below: .
[0019] Preparation Example 2 The method is basically the same as Preparation Example 1, except that Sub13 was purified by reverse phase C18 preparative liquid phase, and eluted by gradient elution with acetonitrile-water (40:60-55:45, v / v) to obtain compound rhazinal (10 mg). The structural formula of rhazinal is shown below: .
[0020] Example 1 Identification of the antibacterial effect of monoterpene indole alkaloids Place a sterilized filter paper (6 mm) on the surface of the PDA agar plate coated with Aspergillus niger, and add 10 μL of the compound solution (10 mg / mL) dissolved in DMSO to the filter paper. Use ketoconazole (10 mg / mL) as the positive control, incubate at 28°C for 3 days, and repeat each sample three times. Figure 1As shown, the diameter of the inhibition zone of Preparation Example 1 is 20.03 mm, the diameter of the inhibition zone of Preparation Example 2 is 29.41 mm, and the diameter of the inhibition zone of ketoconazole is 15.32 mm. Therefore, both Preparation Examples 1 and 2 have strong in vitro antifungal activity and are superior to the traditional antifungal preparation ketoconazole.
[0021] Example 2 Comparison of mycelial growth inhibition rates of monoterpene indole alkaloids Preparation Example 1 and Preparation Example 2 were dissolved in DMSO, mixed with sterilized PDA medium at 50°C, and poured into a culture dish to prepare culture medium containing samples with concentrations of 80, 40, 20, 10, 5, and 2.5 μg / mL. Then, 5 μL of 1 × 10 5 Three test bacterial liquids (Aspergillus niger, Sclerotinia sclerotiorum and Fusarium oxysporum. Among them, Aspergillus niger is a fungus that can cause human diseases, Sclerotinia sclerotiorum and Fusarium oxysporum are common plant pathogenic fungi, and Fusarium oxysporum may also have an impact on human health under certain conditions.) (Aspergillus niger (Aspergillus niger, deposit number CGMCC3.17612), Sclerotinia sclerotiorum (Sclerotinia sclerotiorum, deposit number CGMCC 3.18027) and Fusarium oxysporum (Fusarium oxysporum, deposit number CGMCC 3.2830) were obtained from the China General Microbiological Culture Collection Administration Center) were placed at 28°C and cultured on potato dextrose agar (PDA) medium, and each sample was repeated three times. DMSO and ketoconazole were used as negative and positive controls, respectively, and the results were as follows Figures 2 to 4 shown.
[0022] When the mycelium grows to the edge of the culture dish, the formula is used to calculate: Inhibition rate (%) = 100*(CT) / C Wherein, C is the average growth diameter of mycelium in the negative control group, and T is the average growth diameter of mycelium in the sample group. The inhibition rate comparison results are shown in Table 1. Preparation Example 1 and Preparation Example 2 have different degrees of antifungal effects on Aspergillus niger, Sclerotinia sclerotiorum and Fusarium oxysporum.
[0023] Table 1 Inhibitory effects of Preparation Example 1, Preparation Example 2 and ketoconazole on three fungi .
Claims
1. The use of monoterpene indole alkaloids in the preparation of antifungal drugs, characterized in that: The structural formula of the monoterpene indole alkaloid is shown in formula (A) or formula (B): (A) (B)。 2. The use according to claim 1, characterized in that: The antifungal drugs are drugs used to treat fungal infections in humans, animals and plants.
3. The use according to claim 1, characterized in that: The fungi include one or more of the phylum Ascomycota, Basidiomycota, Deuteromycota, and Zygomycota.
4. The use according to claim 3, characterized in that: The fungi include one or more of Aspergillus niger, Sclerotinia sclerotiorum, and Fusarium oxysporum.
5. The use according to claim 1, characterized in that: The antifungal drugs include monoterpene indole alkaloids and pharmaceutically acceptable salts thereof.
6. The use according to claim 1, characterized in that: The antifungal drug comprises monoterpene indole alkaloids and a pharmaceutically acceptable carrier or auxiliary material.
7. The use according to claim 7, characterized in that: The pharmaceutically acceptable carrier or excipient includes one or more of a diluent, a binder, a lubricant, a solvent, a stabilizer, and a filler.
8. The use according to claim 8, characterized in that: The solvent includes one or more of dimethyl sulfoxide, N,N-dimethylformamide, ethanol, propylene glycol, acetone, and ethyl acetate.
9. The use according to claim 1, characterized in that: The concentration of the monoterpene indole alkaloids in the antifungal drug is 5-100 μg / mL.
